Perplexities of treatment resistence in eating disorders

BMC Psychiatry

Katherine A Halmi¹ 

[1] New York Presbyterian Hospital, Westchester Division, 21 Bloomingdale Rd, Whites Plains, NY 10605, USA

关键词: Binge eating disorder;    Bulimia nervosa;    Anorexia nervosa;    Treatment resistance;   

Others  :  1123903
DOI  :  10.1186/1471-244X-13-292

 received in 2013-04-22, accepted in 2013-09-12,  发布年份 2013

【 摘 要 】

Background

Treatment resistance is an omnipresent frustration in eating disorders. Attempts to identify the features of this resistance and subsequently develop novel treatments have had modest effects. This selective review examines treatment resistant features expressed in core eating disorder psychopathology, comorbidities and biological features. Novel treatments addressing resistance are discussed.

Description

The core eating disorder psychopathology of anorexia nervosa becomes a coping mechanism likely via vulnerable neurobiological features and conditioned learning to deal with life events. Thus it is reinforcing and ego syntonic resulting in resistance to treatment. The severity of core features such as preoccupations with body image, weight, eating and exercising predicts greater resistance to treatment. Bulimia nervosa patients are less resistant to treatment with treatment failure related to greater body image concerns, impulsivity, depression, severe diet restriction and poor social adjustment. For those with binge eating disorder overweight in childhood and high emotional eating predicts treatment resistance. There is suggestive data that a diagnosis of an anxiety disorder and severe perfectionism may confer treatment resistance in anorexia nervosa and substance use disorders or personality disorders with impulse control problems may produce resistance to treatment in bulimia nervosa. Traits such as perfectionism, cognitive inflexibility and negative affect with likely genetic influences may also affect treatment resistance. Pharmacotherapy and novel therapies have been developed to address treatment resistance. Atypical antipsychotic drugs have shown some effect in treatment resistant anorexia nervosa and topiramate and high doses of SSRIs are helpful for treatment of resistant binge eating disorder patients. There are insufficient randomized controlled trials to evaluate the novel psychotherapies which are primarily based on the core psychopathological features of the eating disorders.

Conclusion

Treatment resistance in eating disorders is usually predicted by the severity of the core eating disorder psychopathology which develops from an interaction between environmental risk factors with genetic traits and a vulnerable neurobiology. Future investigations of the biological features and neurocircuitry of the core eating disorders psychopathology and behaviors may provide information for more successful treatment interventions.

【 授权许可】

   
2013 Halmi; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Halmi KA: Perplexities and provocations of eating disorders. J Child Psychol Psychiat 2009, 50:163-169.
• [2]Wagner S, Halmi KA: The sense of personal ineffectiveness in patients with anorexia nervosa: one construct or several? Int J Eat Dis 1987, 6:495-505.
• [3]Halmi KA, Agras WS, Crow S, Mitchell J, Wilson GT, Bryson SW, Kraemer C: Predictors of treatment acceptance and completion in anorexia nervosa. Arch Gen Psychiat 2005, 62:776-781.
• [4]Agras S, Crow S, Halmi KA, Mitchell J, Wilson T, Kraemer H: Outcome predictors for the cognitive – behavioral treatment of bulimia nervosa: data from a multisite study. Am J Psychait 2000, 157:1302-1308.
• [5]Ricca V, Castellini G, Mannucci E, Sauro CL, Ravaldi C, Rotella CM, Faravelli C: Comparison of individual and group cognitive behavioral therapy for binge eating disorder: a randomized, 3 year follow up study. Appetite 2010, 55:656-665.
• [6]Towell DB, Woodford S, Reid S, Rooney B, Towell A: Compliance and outcome in treatment – resistant anorexia and bulimia: a retrospective study. Brit J Clin Psychol 2001, 40:189-195.
• [7]Ricca V, Castellini G, Sauro CL, Mannucci E, Ravaldi C, Rotella F, Faravelli C: Cognitive – behavioral therapy for threshold and sub threshold anorexia nervosa: a 3 year follow up study. Psychother Psycholsom 2010, 79:238-248.
• [8]Hudson J, Pope H, Hiripi E, Kessler R: The prevalence and correlates of eating disorders in the national comorbidity survey replication. Biol Psychiat 2008, 2:1-32.
• [9]Walsh T, Hadigan C, Devlin M, Gladis M, Roose S: Long term outcome of antidepressant treatment for bulimia nervosa. Am J Psychait 1991, 148:12106-12112.
• [10]Kaye W, Bulik C, Thornton L, Barbarich N, Masters K: Comorbidity of anxiety disorders with anorexia and bulimia nervosa. Am J Psychiat 2004, 161:2215-2222.
• [11]Bulik SM, Klump K, Thornton L, Kaplan A, Devlin B, Fichter M, Halmi KA, Strober M, Woodside DB, Mitchell J, Rotondo A, Keel P, Berrettini W, Kaye WH: Comorbidity of eating disorders and alcohol use disorders. J Clin Pychiat 2004, 65:1000-1006.
• [12]Braun DL, Sunday SR, Halmi KA: Psychiatric comorbidity in patients with eating disorders. Psychol Med 1994, 24:859-867.
• [13]Keel P, Mitchell JE: Outcome in bulimia nervosa. Am J Psychiat 1997, 154:331-335.
• [14]Halmi KA, Sunday S, Strober M, Kaplan A, Woodside DB, Fichter M, Treasurer J, Berrettini W, Kaye W: Perfectionism in anorexia nervosa: variation by clinical subtype, obsessionality and pathological eating disorders. Am J Psychiat 2000, 157:1799-1805.
• [15]Tozzi F, Thornton L, Klump K, Fichter M, Halmi KA: Symptom fluctuations in eating disorders: correlates of diagnostic crossover. Am J Psychiat 2005, 10:732-740.
• [16]Stice E, Agras WS, Halmi KA, Mitchell JE, Wilson GT: Subtyping binge eating disordered women along dieting and negative affect dimensions. Int J Eat Dis 2001, 30:11-27.
• [17]Kelly AC, Carter JC, Zuroff D, Borairi S: Self-compassion and fear of self-compassion interact to predict response to eating disorders treatment: a preliminary investigation. Psychother Res 2012, 1:1-13.
• [18]Miller S, Erickson S, Branon C, Steiner H: Habitual response to stress in recovering adolescent anorectic patients. Child Psychiat Humdev 2009, 40:43-54.
• [19]Tchanturia K, Divies H, Campbell IC: Cognitive remediation therapy for patients with anorexia nervosa: preliminary findings. Am Gen Psychiat 2007, 6:14-20. BioMed Central Full Text
• [20]Fox AP, Leung N: Existential well-being in younger and older people with anorexia nervosa – a preliminary investigation. Eur Eat Dis Rev 2009, 17:24-30.
• [21]Wadden YA, Berkowitz RI, Sarier DB, Wisnenieski S, Steinberg C: Benefits of lifestyle modification in the pharmacological treatment of obesity: a randomized trial. Arch Intern Med 2001, 161:218-227.
• [22]Steiger H, Joober R, Isreal M, Young SN, Ng Ying Kin NM, Gauvin L: The 5HTTLPR polymorphism, psychopathological symptoms and platelet paroxetine binding in bulimic syndromes. Int J Eat Disord 2005, 37:57-60.
• [23]Bailer UF, Frank GK, Price JC, Meltzer CC, Becker C, Mathis CA, Wagner A, Barbarich NC, Bloss CS, Putnam K, Schork NJ, Gamst A, Kaye WH: Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa. Psych Res Neuroimag 2012. online
• [24]Bailer UF, Bloss CS, Frank GK, Price JC, Meltzer CC, Mathis CA, Geyer MA, Wagner A, Becker CR, Schork NJ, Kaye WH: 5-HT1A receptor binding is increased after recovery from bulimia nervosa compared to control women and is associated with behavioral inhibition in both groups. Int J Eat Disord 2011, 44:477-487.
• [25]Pichika R, Buchsbaum MS, Bailer UF, Hoh C, Decastro A, Buchsbaum BR, Kahy WH: Serotonin transporter binding after recovery from bulimia nervosa. Int J Eat Disord 2012, 45:345-352.
• [26]Bacanu SA, Bulik CM, Klump KL, Fichter MN, Halmi KA, Keel P, Kaplan AS, Mitchell JE, Rotondo A, Strober M, Treasure J, Woodside DB, Sonpar VA, Xie W, Bergen AW, Berretinni WH, Kaye WH, Devlin B: Linkage analysis of anorexia and bulimia nervosa cohorts using selected behavioral phenotypes as quantitative traits or covariates. Am J Med Genet 2005, 139B:61-68.
• [27]Bloss C, Berrettini W, Bergen A, Magistretti P, Duvvuri V, Strober M, Brandt H, Crawford S, Crow S, Fichter M, Halmi KA, Johnson C, Kaplan A, Keel M, Klump K, Mitchell J, Treasurer J, Woodside DB, Marzola E, Schork M, Kaye WH: Genetic association of recovery from eating disorders: the role of GABA receptor SNPs. Neuropsycholpharm 2011, 36:222-2232.
• [28]Jacobs MJ, Roesch S, Wonderlich SA, Crosby R, Thornton L, Wilfley D, Berrettini W, Brandt H, Crowford S, Fichter M, Halmi KA, Johnson C, Kaplan AS, LaVia M, Mitchell JE, Rotondo A, Strober M, Woodside DB, Kaye WH, Bulik CM: Anorexia nervosa trios: behavioral profiles of individuals with anorexia nervosa and their parents. Psychol Med 2009, 39:451-461.
• [29]Wiseman C, Sunday SR, Klapper F, Harris W, Halmi KA: Changing patterns of hospitalization in eating disorder patients. Int J Eat Dis 2001, 30:61-74.
• [30]Cassano G, Miniati M, Pini S, Rotondo A, Banti S, Borri C, Camilleri V, Mauri M: 6-Month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. Int J Eat Dis 2003, 33:172-177.
• [31]Mehler-wex C, Ronanos M, Kircheiner J, Schulze U: A typical antipsychotic in severe anorexia nervosa in children and adolescents – review and case reports. Eur Eat Dis Rev 2008, 16:100-108.
• [32]Bissada H, Tasca G, Barber AM, Bradwejn J: Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo controlled trial. Am J Psychiat 2008, 165:1281-1288.
• [33]Safer D, Arnow K: Super threshold duloxetine for treatment – resistant depression, anorexia nervosa binge-purging type and obsessive compulsive disorder: a case report. Innov Clin Neurosci 2012, 9:13-16.
• [34]Fairburn CG: Transdiagnostic cognitive behavior therapy for eating disorders. New York: Guilford Press; 2010.
• [35]Tchanturia K, Morris R, Brecelj-Anerluh M: Set shifting in anorexia nervosa: an examination of before and after weight gain, in full recovery in relationship to child and adult OCPD. J Psychiat Res 2004, 38:545-552.
• [36]Money C, Davies H, Tchanturia K: A case study introducing cognitive remediation and emotion skills training for anorexia nervosa inpatient care. Clin Case Studies 2011, 10:110-121.
• [37]Wade T, Treasurer J, Schmidt U: Case series evaluation of the maudsley model for treatment of adults with anorexia nervosa. Eur Eat Dis Rev 2011, 19:382-389.
• [38]Williams KD, Doney T, Geller J: Setting the eating disorder aside: an alternative model of care. Eur Eat Dis Rev 2010, 18:90-96.
• [39]McIntosh VW, Jordan J, Luty SE: Specialist supportive clinical management for anorexia nervosa. Int J Eat Dis 2006, 39:625-632.
• [40]Touyz S, LeGrange D, Lacey H: A randomized control trial of non specific supportive clinical management versus cognitive behavioral therapy in long standing anorexia nervosa. Aus New Zeal J Psychiat 2009, 43(suppl):A13.
• [41]Strober M: Managing the chronic, treatment – resistant patient with anorexia nervosa. Int J Eat Dis 2004, 36:245-255.
• [42]Vanderlinden J, Many roads lead to Rome: Why does cognitive behavioral therapy remain unsuccessful for many eating disorder patients? Eur Eat Dis Rev 2008, 16:329-333.
• [43]Mitchell JE, Agras S, Crow S, Halmi K, Fairburn CG, Bryson S, Kraemer H: Step-care and cognitive behavioral therapy for bulimia nervosa: randomized trial. Brit J Psychiat 2011, 198:391-397. Online March 17
• [44]Martinez-Mallen E, Castro Forniel ESJ, Lazaro L, Moreno E, Morer A, Font E, Julien J, Vila M, Torro J: Cue exposure in the treatment of resistant adolescent bulimia nervosa. Int J Eat Dis 2007, 40:596-601.
• [45]Carter WP, Hudson J, LaLonde JK, Pindyck L: Pharmacological treatment of binge eating disorder. Int J Eat Dis 2003, 34:74-88.
• [46]Kaye W: Neurobiology of anorexia and bulimia nervosa. Physiol Beh 2008, 94:121-135.